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[ Abstract 
A%Tetrahydrocannabinol (THC) is frequently found in the blood of 
drivers suspected of driving under the influence of cannabis or 
involved in traffic crashes. The present study used a double-blind 
crossover design to compare the effects of medium (16.5 mg THC) 
and high doses (45.7 mg THC) of hemp milk decoctions or of a 
medium dose of dronabinol (20 mg synthetic THC, Marinol ~) on 
several skills required for safe driving. Forensic interpretation of 
cannabinoids blood concentrations were attempted using the 
models proposed by Daldrup (cannabis influencing factor or CIF) 
and Huestis and coworkers. First, the time concentration-profiles 
of THC, 11-hydroxy-A%tetrahydrocannabinol (11-OH-THC) 
(active metaholite of THC), and 11-nor-9-carboxy-A% 
tetrahydrocannabinol (THCCOOH) in whole blood were 
determined by gas chromatography-mass pectrometry-negative 
ion chemical ionization. Compared to smoking studies, relatively 
low concentrations were measured in blood. The highest mean 
THC concentration (8.4 ng/mL) was achieved 1 h after ingestion of 
the strongest decoction. Mean maximum t1-OH-THC level 
(12.3 ng/mL) slightly exceeded that of THC. THCCOOH reached 
its highest mean concentration (66.2 ng/mL) 2.5-5.5 h after intake. 
Individual blood levels showed considerable intersubject 
variability. The willingness to drive was influenced by the 
importance of the requested task. Under significant cannabinoids 
influence, the participants refused to drive when they were asked 
whether lhey would agree to accomplish several unimportant 
tasks, (e.g., driving a friend to a party). Most of the participants 
reported a significant feeling of intoxication and did not appreciate 
the effects, notably those felt after drinking the strongest 
decoction. Road sign and tracking testing revealed obvious and 
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statistically significant differences between placebo and 
treatments. A marked impairment was detected after ingestion of 
the strongest decoction. A CIF value, which relies on the molar 
ratio of main active to inactive cannabinoids, greater than 10 was 
found to correlate with a strong feeling of intoxication. It also 
matched with a significant decrease in the willingness to drive, and 
it matched also with a significant impairment in tracking 
performances. The mathematic model II proposed by Huestis et al. 
(1992) provided at best a rough estimate of the time of oral 
administration with 27% of actual values being out of range of the 
95% confidence interval. The sum of THC and 11-OH-THC blood 
concentrations provided a better estimate of impairment han THC 
alone. This controlled clinical study points out the negative 
influence on fitness to drive after medium or high dose oral THC 
or dronabinol. 
Introduction 
Cannabis is the most frequently used illicit drug in the 
Western world. The recreational use nd abuse of cannabis 
have increased considerably during the past few years in 
Switzerland (1) as well as in other European nations (2). Fur- 
thermore, cannabis extracts and marijuana may soon be 
introduced in the Swiss Pharmacopeia. The therapeutic 
potential of cannabis is also under investigation in many 
Western countries (3-5). Synthetic Ag-tetrahydrocannabinol 
(THC) is available on prescription in the U.S., Canada, nd 
several other countries as Marinol | Moreover, hemp is an in- 
gredient of many alternative foods and beverages (6-9). 
Because of its high prevalence, cannabinoids are the most 
frequently detected drugs in blood specimen taken from people 
suspected ofdriving under the influence of drugs or involved 
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in road accidents (10-12). In experimental studies using 
driving simulators and on-the-road driving tests, cannabis im- 
pairs cognition, psychomotor function, and actual driving per- 
formances (11,13,14). However, the simultaneous measure- 
ment of blood cannabinoids concentrations, of psychomotor 
performances, and of driving capability, especially after oral in- 
gestion, has rarely been determined. Furthermore, most of 
these studies have been performed with low to medium doses 
of THC. Drummer et al. (15) reported that increment in crash 
responsibility rates were most prominent at high concentra- 
tions of THC (> 5 ng/mL blood), suggesting that drivers are 
more at risk of being involved in car accidents after exposure 
to high doses of THC. 
The availability ofhemp food products, increase in cannabis- 
based therapeutics, unabated recreational use of oral cannabis, 
and high reported prevalence of drivers under the influence of 
cannabis have prompted th  need to carry out controlled clin- 
ical investigations onoral cannabis to assess its effects on 
driving performances. Our objective was to evaluate the ef- 
fects of an acute oral administration of medium and high doses 
of cannabis extract or of a medium dose of dronabinol 
(Marinol) on the fitness to drive. Before oral administration, 
Ag-tetrahydrocannabinolic acid A (THC-A), the main cannabi- 
noid of hemp, was decarboxylated by heating to yield active 
THC. Then, the kinetic profiles of the major cannabinoids 
[THC, 11-hydroxy-M-tetrahydrocannabinol (11-OH-THC), and 
11-nor-9-carboxy-Ag-tetrahydrocannabinol (THCCOOH)] in 
blood were determined and compared to th  drug effects. First, 
THC is metabolized into active 11-OH-THC which undergoes 
further oxidation to inactive THCCOOH. The oral route was se- 
lected because absorption is sl w, resulting in delayed maximal 
plasma concentrations (usually 60-120 rain after ingestion) 
(16-18). Effects also occur at later times and last longer than 
those observed after smoking. Th s slow and long-lasting pro- 
cess presented more favorable conditions for investigation of 
drug effects through the use of a battery of psychomotor tests. 
It also made the search of a possible correlation between drug 
effects and cannabinoids levels easier. Finally, we used data 
obtained from this study to evaluate two models aimed at eval- 
uation of the time since cannabis exposure from cannabinoids 
blood levels (19,20). The fitness to drive was also assessed 
through different approaches based on the direct interpretation 
of cannabinoids blood concentrations (15,21). These models 
constitute he main strategies for the forensic evaluation of the 
effects of cannabis on driving capability (22). 
Materials and Methods 
Preparation of milk hemp decoctions 
The cannabis tea used as placebo was commercially available 
and was found to contain 0.1% THC and 0.4% cannabidiol. 
Hemp plant fragments containing 1.5% THC and 4.4% THC- 
A were provided by Hiscia institute in Arlesheim, Switzerland. 
The hemp fragments were heated und r argon for half an hour 
in an oil bath at 140~ in order to decarboxylate THC-A into 
THC. The resulting THC concentration was 4.9%. Then THC 
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from 0.41- or 1.22-g hemp fragments containing a total 
mount of 20 or 60 mg THC, respectively, was extracted in 
200 mL hot whole milk for 20 rain. The placebo decoction 
was prepared with 0.8-g hemp fragments containing a total 
amount of 0.8 mg THC. After filtration, the milk was poured 
into a thermos flask, and the THC content was determined by 
high-performance liquid chromatography (HPLC) with diode- 
array (DAD) and fluorescence detection. The average recovery 
of the decoction-making process was about 80%, yielding hemp 
milk decoctions containing 16.5 + 0.9 and 45.7 + 0.7 mg THC 
in 200 mL of whole milk. Marinol, soft gelatin capsules con- 
taining 5 mg dronabinol insesame oil, was provided by Mathias 
Markert (Thun, Switzerland). Cannabinoid standards were pur- 
chased from the Swiss Federal Office of Public Health (THC-A), 
Lipomed (Arlesheim, Switzerland), Cambridge Isotope Lab - 
ratories (Innerberg, Switzerland), or ElSohly Laboratories 
(Oxford, MS). 
Design and participants 
The ethics committee of the Department of Internal 
Medicine of the University of Lausanne approved this double- 
blind crossover study that was carried out to compare the ef- 
fects of 20 mg dronabinol and of 2 hemp milk decoctions con- 
taining either a medium or a high dose of THC with matched 
placebos. Eight male subjects aged 22 to 30 years, all occasional 
cannabis smokers, were enrolled. Volunteers who used any 
other psychotropic drug or had any psychiatric history were ex- 
cluded from the study. Their mean body weight was 72.8 + 5.2 
kg. They were required to abstain from any drug or alcohol 
consumption for one week preceding and during the study. 
Prior to study participation, volunteers provided detailed med- 
ical history, had a medical examination, a d gave written in- 
formed consent. Cannabis and placebo were identical in ap- 
pearance and taste for all treatments. Subjects, caregivers, and 
investigators were blinded to treatment assignment until the 
end of the trial. 
Four gelatin capsules, each containing 5 mg dronabinol in 
sesame oil (total = 20 mg dronabinol), ora matched placebo 
were given to each volunteer. In thesame session, the volun- 
teers received 200 mL of a milk decoction containing a trace 
amount of cannabinoids (placebo decoction) or a medium or 
high dose of THC. The total amount of cannabinoids received 
by the volunteers was therefore (4 possible treatments): traces 
(placebo), 16.5 or 45.7 mg THC, or 20 mg dronabinol. 
The subjects were tested on 4 different occasions a dhad a 
2-week washout period between treatments. The order of ad- 
ministration was balanced (Latin square) and participants were 
randomly allocated to treatment order. About I h before ad- 
ministration, the subjects were tested for the presence ofmajor 
psychoactive drugs (amphetamines, opiates, cocaine, cannabis, 
and benzodiazepines) in urine and for alcohol consumption 
using a breathalyzer. Before and after tre tment, blood was 
taken at regular intervals (0.0, 1.0, 2.5, 4.0, 5.5, 7.0, 10.0, and 
24 h after intake), rapidly frozen, and stored in S-Monovette | 
tubes at -20~ Gas chromatography-mass spectrometry-neg- 
ative ion chemical ionization (GC-MS-NCI) was used for 
cannabinoids etermination. Clinical observations and two 
psychomotor tests (roadsign and tracking testings) were also 
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carried out. Furthermore, th  subjects were asked to report 
their willingness to drive under various circumstances and 
the subjective effects were measured on a visual analog scale 
(VAS) on a continuous scale from 0 to 10 cm. Overall, 240 ob- 
servations with blood samplings were undertaken. 
Extraction and determination of cannabinoids by 
HPLC-DAD.fluorescence in hemp powder and 
hemp milk decoction 
Hemp owder. Ten milliliters of dichloromethane/methanol 
(1:9 v/v) was added to 200 mg hemp owder. After 15 min in an 
ultrasonic bath, e extract was centrifuged for 10min at 2500 
rpm. Twenty microliters was collected and diluted with 980 IJL 
methanol. After vortex mixing, 10 IJL was analyzed by 
HPLC-DAD-fluorescence detection. 
Milk extraction. From 1 mL of filtrated milk, 100 I~L was 
taken and added to 900 IJL methanol in a 1.5-mL Eppendorf 
tube. After vortex mixing and 10 rain centrifuging in a Ep- 
pendorf 5417R microcentrifuge at maximum speed (14,000 
rpm), the supernatant was transferred to another Eppendorf 
tube and 10 IJL were injected into the HPLC. 
HPLC-DAD-fluorescence analysis of cannabinoids. An Agi- 
lent 1100 HPLC was used for the quantification ofcannabi- 
noids in plant and milk extracts. The liquid chromatography 
system consisted of a vacuum degasser, quaternary pump, au- 
tosampler, and thermostatted column compartment. Ten-mi- 
croliter injections were made onto an XTerra MS C18 column 
(Waters, 150- • 2.1-mm i.d., 3.5 I~m) that was held at 25~ The 
mobile phase A consisted of 95:5 (v/v) of 10raM KH2PO4 ad- 
justed to pH 7.5 with KOH and acetonitrile. Mobile phase B was 
100% acetonitrile. The cannabinoids were separated at a flow- 
rate of 250 IJL/min using a mobile phase gradient. After a 1-min 
hold, the B percentage was increased from 40% to 80% by 19 
rain. The final composition was held for another 7 min and 
then returned to starting composition in 1 min. An Agilent 
1100 (DAD) and an Agilent fluorescence detector were used for 
tentative identification and quantification. Monitoring with 
DAD was performed at210 nm (5 nm bandwidth). The excita- 
tion wavelength for both THC and THC-A was set at 222 nm. 
THC-A and THC fluorescence were monitored at 403and 313 
nm, respectively. When monitored at 210 nm, the retention 
times for AO-THC-A was 11.97 rain and those for Ag-THC and 
AS-THC of 24.74 and 24.96 min, respectively. Quantitation was 
performed by the external standard method, measuring the 
peak areas. 
Quantification of THC, 11-OH-THC, and THCCOOH in 
whole blood by GC-MS operating in the NCI mode 
The method used for the determination f cannabinoids in 
whole blood was adapted from Giroud et al. (23) for the ex- 
traction part and from Huang and co-workers (24) for the 
GC-MS-NCI part. To 1 mL of whole blood, THC-d 3, ll-OH- 
THC-d3, and THCCOOH-d9 (Lipomed, CIL) at a concentration 
of 20 ng/mL were added. After protein precipitation with ace- 
tonitrile, ultrasonic treatment, and centrifugation, the cannabi- 
noids were extracted through C18AR SPEC TM (Varian) 30-rag 
extraction columns. After elution from the SPEC column and 
evaporation u der a stream of nitrogen, the dried residue was 
derivatized for 10 min at 70~ in the presence of 150 1JL of 
chloroform, 150 IJL trifluoroacetic anhydride, and 50 I~Lhex- 
afluoroisopropanol. After evaporation, the derivatized residue 
was reconstituted with 50 IJL of heptane, and 2 IJL was splitless 
injected into he GC. Analyses were performed on an Agilent 
6890N GC interfaced with an Agilent 7683 autosampler and  
Agilent 5973N MS. The GC column was an HP 1 MS column 
(12 m x 0.2 mmx 0.33 l~m). Helium at a rate of 1.2 mL/min 
was used as carrier gas. The initial oven temperature was set at 
150~ for 1 rain, and then increased to 232~ at a rate of 
25~ to 240~ at a rate of 4~ and to 300~ at a 
rate of 25~ This final temperature was maintained for 
1 rain. Temperatures of the injector port, interface, and source 
were 260, 280, and 150~ respectively. Methane t a flow of 
40% of total flow (5 mL/min) was used as reagent gas. The MS 
was operated in the SIM mode, the following ions were moni- 
tored; m/z 410 (THC), m/z 413 (THC-d3), m/z 408 (11-OH- 
THC), m/z 411 (11-OH-THC-d3), m/z 590 (THCCOOH), and 
m/z 599 (THCCOOH-dg). The ion at m/z 408 is obtained 
through loss of the trifluoroacetic group (CF3COOH) from the 
di-trifluoroacetyl derivative. Linearity w s determined with 
whole blood samples spiked with increasing concentrations of 
cannabinoids ranging from 0.3 to100 ng/mL and from 0.8 to 
50 ng/mL for THC and 11-OH-THC, respectively and from 0.1 
to 100 ng/mL for THCCOOH. The correlation coefficients (r 2) 
were found to be higher than 0.999. Coefficient of variation 
(CV) for intra- and interassay precisions were calculated at 
three concentrations (2.0, 10.0, and 50.0 ng/mL) for each 
cannabinoid (triplicate determination). Overall, intra- and in- 
terassay CVs were below 11.2% and 6.8%, respectively. The 
method was accurate at all tested concentrations t  within 
10%of the target concentration. The limits of quantification 
were below 1.0 ng/mL for all three cannabinoids (THC: 0.3 
ng/mL, ll-OH-THC: 0.8 ng/mL, and THCCOOH; 0.1 ng/mL). 
The extraction recovery was found to be higher than 50%. 
Each batch included a blank blood sample and a blood sample 
fort fied with the internal standards only to evaluate the se- 
lectivity of the method. No significant interferences could be 
detected. The cannabinoids were found to be stable for at le st 
two months when the blood samples were stored at-20~ and 
preserved with 1.2 mg EDTA and 1.0 mg fluoride/mL blood in 
S-Monovette ubes (Sarstedt, Sevelen, Switzerland). 
Clinical observations 
Subjects were observed for objective signs of drug influ- 
ence. Conjunctival reddening was visually assessed, and graded 
from I to 4. Pulse rate and arterial pressure were also recorded. 
Subjective ffects rating scale 
The feeling of intoxication (i.e., the intensity of "high") was 
reported by the participants on a VAS scale xtending from 0 
(no effect) to10 cm (maximum effect experienced in the past 
while smoking marijuana). The respondents indicated their 
answer to the question "do you feel intoxicated by cannabis?" 
by drawing an intersecting line through the 10-cm line. The 
appreciation ofdrug effect (i.e., "drug liking") wasalso re- 
ported on a VAS scale extending from 0 (unpleasant), to 5 (un- 
noticeable), to 10(pleasant). 
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Willingness to drive and feeling of inability to drive 
The willingness to drive is often used to assess the self-re- 
ported deterioration i psychomotor performance following 
drug or alcohol exposure (25). The willingness to drive was 
evaluated by asking several questions of great or minor im- 
portance to the participants. The agreement to drive a pas- 
senger under various emotional nd rewarding circumstances 
was the main focus of these tests. The following questions 
were asked: (a) do you agree to immediately drive an ill child 
to the hospital? (b) do you agree to drive a moderately sick 
friend home? (c) do you agree to drive a friend to a party? and 
(d) do you assess your driving capability to be significantly de- 
creased? The volunteers reported the results on a continuous 
0-10 cm VAS. 
Psychomotor and driving simulator testing 
These tests are commonly used by the Swiss Society of 
Traffic Psychology (http://www.vfv-spc.ch/vfv_franz/index.htm) 
(26). The usefulness of driving simulators in clinical practice 
has been reviewed recently (27). 
Roadsign testing. Twenty pairs of roadsigns were shown in a 
random order on a screen. Ablinking arrow pointed to a single 
roadsign and the subject was asked to find out the corre- 
sponding partner of the pair. Below the second roadsign was a 
number. This number was also found on a touch-screen i  
front of the participant. The last task for the subject consisted 
in pressing the key with the corresponding umber. The total 
time to detect all pairs of roadsigns was measured. This test 
mainly consists of a visual search task. The speed of visual 
processing and short term memory as well as accurate per- 
ception play a decisive role in this test. 
Tracking test. The tracking test consisted of two subtasks. 
First, the subject was asked to keep a symbolic vehicle withthe 
help of a steering wheel on the main track. Secondly, the sub- 
ject was asked to press the left or right foot pedal when specific 
signals appeared to the left or the right of the track. Disturbing 
signals and dead-end roads appeared also. The percentage of
time in the track as well as the number of errors were recorded. 
The following parameters were assessed: continuous dynamic 
steering, anticipating perception and pertinent reaction to rel- 
evant and disturbing signals, psychomotor coordination, and 
level of vigilance. 
Statistical interpretation 
Significance of the results of psychomotor tests and of the 
driving simulator testing were evaluated using the Statistical 
Package for the Social Sciences (SPSS | 11.0 for Windows). The 
nonparametric test of Kruskal-Wallis was u ed to evaluate the 
results of roadsign testing, driving simulator, and of the sub- 
jective effects and willingness to drive. Pair-wise t sts (Tukey 
test) were used to detect differences between treatments. Ki- 
netic profiles were processed with the Winstat software (Statis- 
tics Add-In for Microsoft | Excel). The pharmacokinetic pa- 
rameters were assessed with the PK Analyst software (PK 
Analyst for Windows: Pharmacokinetic data analysis version 1.1 
for Microsoft Windows, MicroMath Scientific Software). 
PKmodel # 12 and 14 were selected for the evaluations ofthe 
THC, 11-OH-THC, and THCCOOH kinetics. 
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Interpretation of the results 
Forensic interpretation fresults. The cannabis influencing 
factor (CIF) has been proposed by Daldrup's group (21). The 
CIF is the molar ratio between the sum of THC and 11-OH- 
THC concentrations and THCCOOH level multiplied by 100. 
Anyone with a CIF value over 10 is presumably as unfit to 
drive as one with a blood-alcohol concentration (BAC) value of 
1.1 g/kg. CIF parameter can be used on the condition that the 
blood is drawn between 0.5 and 1.5 h after the event. Consid- 
ering a specific time-period (1994) and specific area in Ger- 
many (DUsseldorf), about 3/4 of the drivers involved in car ac- 
cidents or having committed serious driving errors (e.g., 
getting off the roadway) under the influence of alcohol or 
cannabis were found to have a BAC value higher than 1.1 g/kg 
or a CIF value higher than 10. 
Assessment ofthe time since exposure. Two mathematical 
models have b en proposed that estimate the time of marijuana 
exposure from a single plasma measurement of THC alone or 
of both THC and THCCOOH and provide accompanying 95% 
confidence interval (16,20). Model I is based on THC concen- 
trations, and model II relies on THCCOOH/THC ratios. Equa- 
tions are shown in Huestis et al. (20). 
Interpretation of blood levels. Various pharmacodynamic 
models have been proposed to estimate pharmacological ef-
fects. The majority provide concentrations e timated in the 
range of 5-29 ng THC/mL necessary for a significant subjective 
"high" effects ordriving impairment. For instance, a significant 
linear correlation was found between tracking errors under di- 
vided attention and THC plasma levels over 5-25 ng/mL for ap- 
proximately 2 h after smoking (28). This approach isdiscussed 
in several reviews (14,16). 
Results and Discussion 
Selection of whole milk as a vehicle for THC administration 
and efficiency of the hemp decoction making process 
Because of its poor water solubility, THC was administered 
in a fat-rich matrix. Dronabinol was solubilized in sesame oil 
and plant cannabinoids inwhole milk containing 2.7% of milk 
fat. In Pakistan and India, "bhang" is a beverage that is made 
from an infusion of cannabis leaves and flowering tops com- 
bined with milk and nuts (29). Consumption of this milk de- 
coction is quite common; its preparation is relatively similar to 
the beverage that was used in this study. The recipes for 
making hemp milk decoctions can also be found in many 
underground publications (30) or on internet dedicated 
web sites (e.g., http://cannabisculture.com/backissues/ 
cc00/cooking.html). 
Fresh cannabis plant material contains mainly THC-A as 
the major cannabinoid, typically about 80%. Before oral ad- 
ministration, THC-A must be decarboxylated into active THC. 
This process is accomplished by heating through several 
methods (6,31). Heating a "space cake", brownies, or cookies in 
an oven at 180~ results in the almost complete transforma- 
tion of THC-A to THC. Drinking a decoction made with 
cannabis will produce more or less effect depending on the 
Journal of Analytical Toxicology, Vol. 29, July/August 2005 
fraction of THC present at the end of the heating process. The 
thermal pretreatment of he cannabis plant fragments made 
easier the preparation ofa hemp decoction containing a well- 
defined ose of THC. 
Because only partial conversion ofTHC-A into THC was ac- 
complished by heating hemp plant fragments inmilk for I h at 
93~ we decided to heat the hemp powder under argon at 
140~ for half an hour. After this thermal pretreatment, THC 
only, but neither THC-A nor cannabinol, could be detected in
the powder by HPLC. This powder was used to prepare a milk 
decoction. The analysis of the hemp decoction revealed the 
presence ofTHC with a minor amount of cannabidiol. About 
80% of the THC dose was recovered from the filtrated decoc- 
tion. Part of the THC was very likely lost during the heating of 
the milk or the filtration step carried out to remove most of the 
hemp herb fragments. 
Criteria for the selection of the dose 
In previous studies, wehave reported the effects and the 
cannabinoids kinetics of the orally administered hemp water 
and milk decoctions (18). Moderate subjective clinical effects 
(about 50% of the maximum effect felt in previous experi- 
ences) were ported after drinking the hemp milk decoction. 
The maximum concentrations of THC and 11-OH-THC were 
found to be lower than 5.0 ng/mL. The ingested dose was 23.2 
mg THC. A review of the controlled administration studies 
has shown that he dose administered through the oral route 
varies considerably, from 2.5 g up to about 60 mg THC. The 
daily dose also varies considerably, reaching a maximum 
amount of about 210 mg administered orally as capsules con- 
taining 30 mg of THC in sesame oil, with 60 mg given prior to 
sleep (32). Generally, the therapeutic dose is relatively low to
minimize the behavioral effects characteristic to marijuana 
and the risks of unwanted side effects (5,33). Recreational 
use of oral cannabis may involve very high doses with unpre- 
dictable effects because ccurate stimation of the ingested 
dose is almost impossible and also because the psychotropic ef- 
fects are delayed (30,34). Fifty to about 400 mg of THC per day 
represent the typical dose ofchronic heavy cannabis smokers. 
The oral doses administered in this study can therefore be 
considered as a medium and a high single close of THC. 
Adverse events 
Unwanted psychiatric side-effects. Two of the 8 subjects 
were withdrawn from the study after administration f dron- 
abinol or of the hemp milk decoction containing the medium 
dose of THC. The first participant experienced strong anxiety 
with paranoid feelings after drinking a milk decoction con- 
taining 16.5 mg THC, while the second one experienced anx- 
iety with altered perception of reality after ingestion of 20 mg 
of dronabinol. Fortunately, all unpleasant effects resolved spon- 
taneously within o e day. Cannabis psychosis following bhang 
ingestion has been already reported (29). The symptoms in- 
cluded grandiosity, excitement, hostility, uncooperativeness, 
disorientation, hallucinatory behavior, and unusual thought 
content. Dysphoric reactions to cannabis are not uncommon, 
especially in na'fve subjects (4,35). 
Gastrointestinal side-effects. Nausea was often reported. 
Vomiting was also observed, especially after ingestion of the 
milk decoction containing the high dose of THC. These ef- 
fects were more pronounced when the active cannabinoids 
reached their highest concentrations. Cannabis and synthetic 
THC (dronabinol) or Nabilone have been advocated for the 
prevention ofnausea nd vomiting caused by anticancer d ugs 
(3). Low doses of THC are generally prescribed to induce anti- 
emetic effects. However, the opposite effects were observed in 
our study with larger doses. High doses r chronic use can in- 
deed induce pro-emetic effects (3,36). Nausea andvomiting 
were also observed after in ravenous injection of marijuana 
(37). Vomiting is likely to be the consequence of peripheral and 
central actions. THC alters gastric emptying of solid food in hu- 
mans, inhibits gastric acid secretion, decreases gastrointestinal 
motility, and selectively acts onCB1 receptors in specific re- 
gions of dorsal vagal complex (38--40). All these ffects may in- 
hibit or stimulate mesis depending on the ingested dose and 
of the presence of co-ingested food and beverages. Simulated 
driving and watching amoving vehicle on a screen could also 
enhance the nausea experienced by the volunteers. In our 
study, this was obviously a triggering or aggravating factor for 
several subjects. These adverse effects may also happen in "real 
life" conditions while driving on a sinuous road under the in- 
fluence of cannabis. 
Urine screens, breath ethanol levels, and blood 
cannabinoids concentrations at the beginning of 
each session 
Screens carried out with immunoassays and breathalyzer 
showed no detectable l vels of major psychoactive drugs in 
urine or breath ethanol. No cannabinoids were found in blood 
of the participants before treatments. 
Blood kinetics of THC, 11-OH-THC, and THCCOOH 
Mean blood levels of THC, ll-OH-THC, and THCCOOH for 
all 8 subjects (6 participants for the high dose) following in- 
gestion of 20 mg dronabinol, or 16.5 + 0.9 mg THC or 45.7 + 
0.7 mg THC as a milk decoction are shown in Figure 1. Table 
I lists the mean maximum cannabinoids levels, average con- 
centrations, and concentration ranges for the one-day time 
period following dronabinol and decoction ingestions. No 
cannabinoids could be detected in blood following adminis- 
tration of the placebo gelules and decoction (results not 
shown). The time-concentration curves in Figure 1A demon- 
strate that THC was rapidly detectable in whole blood and pre- 
sent for several hours, with average peak concentrations oc- 
curring already 1 h after ingestion. Maximum mean THC 
concentrations were in the same range (2.8 and 3.8 ng/mL) 
when similar doses were administered, regardless of the type of 
vehicle used (milk decoction or capsule filled with sesame oil) 
(Table I). A 2.2- to 3.0-fold increase in peak concentration was 
observed after d inking the 45.7 mg THC-decoction. Inges- 
tion of the decoctions resulted in mean THC that decreased 
rapidly after the peak. The mean THC levels remained in the 
same range for a longer time (1-5.5 h) after intake of dron- 
abinol. The individual results show there as a considerable in- 
tersubject variability. This high variability is llustrated by the 
individual THC kinetics determined after ingestion of the milk 
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Figure 1. Whole blood levels of mean THC, 11 -OH-THC, and THCCOOH and individual THC levels for 8 subjects (6 particpants for the decoction containing 
45.7 mg THC) after ingestion of 20 mg dronabinol or a milk hemp decoction containing a mean dose of 16.5 or 45.7 mg THC. 
Table I. Mean Whole Blood Concentrations of THC, 11-OH-THC, and THCCOOH and Concentrations Ranges After 
Administration of 20 mg Dronabinol and of 2 dL of Hemp Milk Decoction Containing Either 16.5 or 45.7 mg THC* 
1 h 2.5h 4h 5.5h 7h 10h 24h 
THC ~g/L 
Dronabinol Mean 2.8 2.1 2.4 1.7 0.9 0.4 nd 
20 mg Range nd-5.6 nd-5.0 nd-6.3 nd-3.7 nd-1.7 nd-1.4 nd-0.3 
Decoction Mean 3.8 2.5 1.1 0.9 0.8 0.4 < LOQ 
16.5 mg THC Range 1.5-8.3 0.6-6.2 nd-3.6 nd-2.7 nd-2.3 nd-1.7 nd-0.9 
Decoction Mean 8.,1 5.5 3.4 3.5 2.2 0.9 0.3 
45.7 mg THC Range 3.9-13.1 1.6-9.0 0.8-5.1 0.4-10.5 < LOQ-7.7 < LOQ-1.7 nd-1.1 
11-OH-THC pg/L 
Dronabinol Mean 2.4 2.6 3.9 3.2 2.3 1.0 nd 
20 mg Range nd-6.3 nd-5.2 1.4-8.5 < LOQ-8.4 < LOQ-6.0 nd-2.2 nd 
Decoction Mean 4.7 3.2 2.4 1.0 0.9 < LOQ nd 
16.5 mg THC Range 2.9-7.0 < LOQ-5.6 nd-4.3 nd-2.7 nd-2.7 nd-l.5 nd 
Decoction Mean 12.3 12.8 7.9 7.1 4.9 2.5 1.1 
45.7 mg THC Range 4.6-23.8 3.4-24.7 1.7-15.1 1.6-21.0 1.1-17.0 < LOQ-8.2 nd-5.0 
Tnccoon ~g/L 
Dronabinol Mean 11.2 19.0 24.7 27.8 23.6 18.0 10.1 
20 mg Range 2.5-25.0 2.8-35.5 8.547.5 5.4-55.4 3.746.4 2.5-35.8 2.8-21.5 
Decoction Mean 22.4 27.2 27.8 20.2 17.6 13.6 8.2 
16.5 mgTHC Range 13.3-31.4 7.7-41.0 14.1-42.4 4.5-39.7 4.3-35.3 3.2-27.2 2.3-15.5 
Decoction Mean 49.4 66.2 56.2 49.3 43.9 33.1 24.3 
45.7 mg THC Range 24.8-85.3 29.0-99.9 31.1-90.6 20.5-85.4 19.9-86.8 13.6-66.6 6.8-64.5 
* Maximal concentrations are bold-typed and underscored. < LOQ = lower than the limit of quantification and nd = lower than the limit of detection. 
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decoction containing the average dose of 45.7 mg of THC (6 in- 
dividual curves shown i  the Figure 1D). Maximum individual 
levels ranged from 3.9 to 13.1 ng/mL (Table I) and THC re- 
mained etectable inwhole blood for a time period of 10-24 
hours. The area under the curve for the mean data from 0 to 24 
h did not show significant differences between dronabinol and 
the milk decoction containing the medium dose. However, a 
two-fold increase was noticed after drinking the decoction 
containing the strongest dose (results not shown). 
The active metabolite 11-OH-THC, was detectable in higher 
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Figure 2. Mean subjective effects and willingness to drive after ingestion of the placebo (,), 20 mg dronabinol (i), 16.5 mg THC (*), or 45.7 mg THC (A) in hemp 
milk decoctions. Differences between treatments and placebo were statistically significant (Kruskal-Wallis test, p < 0.0001). Pair-wise comparisons were also 
significant for each treatment versus placebo (Tukey test, p < 0.05). 
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mean concentrations than THC for all treatments. For in- 
stance, THC and 11-OH-THC levels reached a m ximum ean 
concentration f 8.4 and 12.3 ng/mL, respectively (Figures 1A 
and 1C). Taking into account a plasma/whole blood distribu- 
tion ratio of 1.6 (23), a 11-OH-THC plasma concentration f 
19.7 ng/mL could be calculated. The maximum individual 
concentration was 24.7 ng/mL whole blood (i.e., 39.5 ng/mL 
plasma). This maximum plasma concentration is significantly 
higher than those (3.8-16.0 ng/mL) which were determined 
after smoking a marijuana cigarette containing 3.55% THC 
(19). In our study, mean peak levels were noted 1-4 h post-in- 
gestion. 11-OH-THC remained etectable inwhole blood for 
10-24 h depending on the dose, which was ingested (low 
versus high dose). It is interesting to note that the highest 
mean and individual sum of THC + 11-OH-THC levels, the two 
main active cannabinoids, were 20.7 and 36.9 ng/mL whole 
blood, corresponding to maximum plasma levels of about 32.1 
and 57.2 ng/mL. These concentrations are significantly less 
than active cannabinoids levels which are typically measured 
after smoking a marijuana cigarette containing a medium 
amount of THC (> 100 ng/mL of plasma). The mean [11-OH- 
THC]/[THC] ratios ranged from 0.86 to 2.56 for the whole 
range of treatments. A similar range ofvalues can be calcu- 
lated in the late elimination phase when THC and 11-OH- 
THC reach low plasma levels after cannabis moking (< 3 
ng/mL plasma) (19). 
Mean THCCOOH concentrations in whole blood reached 
their maximal value later on, between 2.5 and 5.5 h after drug 
ingestion. The levels were also much higher than those deter- 
mined for THC and 11-OH-THC with mean maximum values 
of 27.8, 27.8, and 66.2 ng/mL, after ingestion of 20 mg dron- 
abinol, of 16.5 and 45.7 mg THC, respectively. THCCOOH was 
still present in significant levels 24 h following ingestion 
(Figure 1B and Table I) with one participant showing a max- 
imum concentration f 64.5 ng/mL. The mean maximum con- 
centration calculated after 1 day post-ingestion was in the 
range 10.1-24.3 ng/mL. In contrast with what is generally ob- 
served after cannabis smoking, the THCCOOH concentrations 
remained significantly higher at all times than those of THC 
and 11-OH-THC. 
Objective effects 
A slight to moderate conjunctival reddening was consis- 
tently observed. The reddening was more intense after drinking 
the 45.7-mg decoction. The extent of reddening reached its 
highest level (mean score = 2.2) after 1.0-2.5 h and then de- 
creased continuously to reach baseline levels after one day. 
Similar effects have already beenobserved following various 
routes of administration (41,42). A slight to moderate tachy- 
cardia was noted after hemp milk decoction administration as 
well as dronabinol ingestion. For instance, the pulse increased 
from a mean value of 58 to 85 bpm 1 h after ingestion of the 
45.7-mg decoction. 
Subjective effects and willingness to drive 
The volunteers eported the subjective effects and willing- 
ness to drive on an visual analog scale (0 to 10 cm). When com- 
pared to placebo, obvious cannabis influence was observed 
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under almost all treatments (Figure 2). These differences were 
also statistically significant (Kruskal-Wallis test, p < 0.0001). 
On the whole, pair-wise comparisons were also statistically 
significant for each treatment versus placebo (Tukey test, p < 
0.05). However, most pair-wise comparisons between tr at-
ments were not significant. We found a moderate degree of ac- 
ceptance when an absolutely vital demand was addressed tothe 
participants [e.g., do you agree to drive an ill child to the hos- 
pital? (Figure 2C)]. On the other hand, we found a strong re- 
fusal when the subjects were asked a question of less impor- 
tance [e.g., do you agree to drive a friend toa party? (Figure 
2A)]. Robbe (25) has previously reported tha  he willingness to 
drive decreased with increasing doses of cannabis. He also 
found that the willingness to drive was greatest for urgent 
trips and increased with time. These r sults uggest that the 
subjects were able to balance the importance ofthe trip against 
the risk of having an accident. The participants were aware of 
the effects of the drug and reported a strong feeling of"high". 
The self-reported intoxication was more intense after ingestion 
of the highest dose (Figure 2E). Liguori et al. (43,44) have 
also shown that self-report ratings of "high" and "drug po- 
tency" as well as the feeling of impairment increased with the 
A 
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Figure 3. Mean results of roadsign and tracking testings. Differences be- 
tween treatments and placebo were found to be statistically significant 
(KruskaI-Wallis test, p < 0.0001 ). Pair-wise comparisons were also statisti- 
cally significant for each treatment versus placebo (Tukey test, p < 0.05). 
Pair-wise comparisons between treatments were not significant. 
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smoking dose. However, our subjects did not appreciate he ef- 
fects, especially after drinking the decoction containing the 
highest dose of THC. The ingestion of capsules containing 7.5 
or 15 mg THC to assess subjective and cognitive effects has an 
opposite effect producing increased ratings of liking (45). The 
volunteers also had the feeling that their driving capability 
was deeply impaired (Figure 2F). Dysphoric effects and nausea, 
which are often felt after ingestion of medium to high doses of 
THC and possibly triggered or enhanced by the simulated 
driving task, may explain why the volunteers did not like the ef- 
fects. Lack of tolerance may be a contributing factor. Calhoun 
et al. (46) have shown that dronabinol given orally does n t 
provide the effects that are considered desirable in a drug of 
abuse. The onset of action is slow and gradual, it is at most only 
weakly reinforcing, and the overwhelming majority of reports 
of users indicate that its effects are dysphoric and unappealing. 
The large differences in effects between smoked and ingested 
cannabis have several explanations. First, the k netics are dif- 
ferent, secondly, more metabolites are p oduced through first- 
pass metabolism after oral intake. 11-OH-THC, could be more 
dysphoric than THC. However, 1mg of 11-OH-THC adminis- 
tered intravenously produces psychological and pharmacolog- 
ical effects hat mimic those of THC (47,48). In addition, THC 
and 11-OH-THC were equipotent when infused IV with 25% 
human serum albumin in 2-3 mg doses (49). Other active 
metabolites could be also involved. Thirdly, oral ingestion po- 
tentially produces more adverse effects on the gastrointestinal 
tract. Adverse reactions, such as abdominal pain, nausea, and 
vomiting with an incidence of 3-10% were indeed r ported by 
Unimed Pharmaceuticals, the company marketing Marinol | 
Finally, the route of administration could influence the body 
and brain distribution f cannabinoids (50). In a cocaine fatality 
associated with coingestion of marijuana, THC, and 11-OH- 
THC were found to be present in higher concentrations in 
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Figure 4. Comparison of subjective rating of intoxication (VAS .) to cannabis influencing factor (CIF o) as proposed by Daldrup and Meininger (21) (A) and 
comparison of Tracking results (*)to CIF values (B). 
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Figure 5. Mathematical models for the prediction of time of marijuana exposure according to Huestis t al. (20) and actual values obtained in this study. 
Model I is based on THC concentrations (A), and Model II is based on plasma [THCCOOH]/[THC] ratios (B). Dotted lines represent 95% confidence intervals. 
Plasma concentrations were calculated from whole blood levels determined in this study after ingestion of 20 mg dronabinol, 16.5 mg or 45.7 mg THC in 2 dL 
hemp milk decoctions. Calculated plasma levels (x) were fitted in both models. 
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brain cortex than in whole blood (51). Their overall effect 
could depend on their espective concentrations and molar 
ratios in target brain structures. 
Roadsign and driving simulator testing 
Figure 3 shows the mean results of the roadsign testing. 
The differences between placebo nd oral THC were statistically 
significant (p < 0.0001). The total time to achieve the pairing 
of the 40 road signals was deeply increased after drinking the 
decoction containing 45.7 mg THC. The impairment was es- 
pecially noticed during the time period ranging from 1.0 to 5.5 
h post ingestion. More obvious effects were detected with the 
driving simulator. When considering the results of the tracking 
test, the performances ofthe participants were strongly im- 
paired. All treatments differ statistically from the placebo (16.5 
mg THC-decoction: p < 0.003; 20 mg dronabinol: p < 0.001; 
45.7 mg THC-decoction: p < 0.0001). However, nonparametric 
statistical tests did not reveal differences between vehicles 
(milk or sesame oil containing gelules) and doses (16.5 or20 
mg versus 45.7 rag) probably because of th small sample size. 
Nevertheless, the maximum decrease in tracking efficiency 
was noticed after taking the highest dose. Irrelevant errors 
(e.g., pressing the pedal when a disturbing signal appears) as 
well as reaction time were less affected. A moderate increase in 
reaction time was detected after oral ingestion of dronabinoI r 
THC. This effect was not statistically significant. Therefore, 
keeping a symbolic vehicle on the track was the most difficult 
task for the participants under the influence of cannabis. In 
agreement with these results, Robbe and coworkers (52,53) 
have shown that standard deviation of lateral position in the 
road-tracking test was the most sensitive measure for revealing 
THC's adverse effects. 
Forensic interpretation of results 
CIR CIF (21) was calculated from the actual concentrations 
of THC and its two main metabolites. Figure 4 indicates that 
mean CIF values higher than 10 matched the mean intoxica- 
tion level rated by the volunteers a  well as the mean decrease 
in tracking efficiency. Similar relationships were notic d with 
the 3 active treatments. However, the kinetics were very dif- 
ferent with the CIF showing an almost continuous decrease 
while the subjective ffects and the tracking performance 
records showed a more bell-shaped curve. The CIF reached its 
maximum before the strongest feeling of intoxication and the 
maximum tracking impairment. During the first hours fol- 
lowing ingestion, the CIF value was decreasing while th  rating 
of intoxication and the impairment level were increasing. These 
results uggest that the absolute value of the CIF must not be 
used to assess the severity of intoxication or impairment. Nev- 
ertheless, these results uggest that the cut-off of 10 could be 
roughly used todiscriminate between unfit and capable drivers. 
Calculation of the time of ingestion. Huestis et al. (19,20) 
proposed two mathematical models aimed at the prediction of 
the time of cannabis moking. These models have also been 
suggested to assess the time of oral intake. Model II was 
claimed to be more accurate after marijuana ingestion. Our re- 
sults show that 56% and 27% of the values were out of the 
range of the confidence intervals of Models I and II, respectively 
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(Figure 5). Model I tended to underestimate th  actual time of 
ingestion, whereas Model II tended to overestimate the ti e of 
intake. Model II should be preferably used because it was more 
accurate, but also because in forensic practice, theinterpreta- 
tion of results must be in favor of the suspected driver. 
Blood concentrations. Drummer et al. (15) recently showed 
that 58 drivers killed in road traffic crashes with measurable 
THC concentrations i  their blood had a significantly higher 
likelihood of being culpable than drug-free drivers. The odds 
ratio was 6.6 for drivers with blood THC concentrations greater 
or equal to 5 ng/mL. In our study, we found that 20, 36, and 61 
out of 154 cannabinoids determinations showed respective 
THC, 11-OH-THC, and THC + 11-OH-THC blood concentra- 
tions greater than 4.6 ng/mL. When considering the mean 
values, THC levels were below 5.0 ng/mL, although several 
tests were indicative of significant impairment. A better ela- 
tionship was found when considering the sum of THC and 11- 
OH-THC. Without aking into account a slight difference in 
molecular weight, the sum of THC and ll-OH-THC remained 
higher than 4.6 ng/mL for 7 h after ingestion of the decoction 
containing 45.7 mg THC. This time period matched with a 
significant impairment in tracking performances ( ompare 
Figures I and 3). 
Conclusions 
Our study shows that although large doses of THC were in- 
gested and obvious psychoactive effects observed and p rfor- 
mance impairments monitored, blood levels of THC and of 
11-OH-THC remained lower than 13.1 and 24.7 ng/mL, re- 
spectively. A two- t  threefold increase in cannabinoid blood 
concentrations was achieved following ingestion of the milk 
hemp decoction containing the highest dose (45.7 rag). The 
willingness to drive was significantly hampered after all treat- 
ments. Important effects were also noticed with the roadsign 
testing and the tracking test. Altogether, the results indicate 
that oral ingestion of cannabis or dronabinol in medium and 
high doses can severely impair several performance skills re- 
quired for safe driving. Finally, three strategies (the first aimed 
at the estimation ofthe time of cannabis exposure, th  second 
with the objective to assess the fitness to drive, and the third 
based on the interpretation f blood levels) were evaluated 
under our specific experimental setting (i.e., oral intake of a 
medium or high dose of THC). Our results show that Model II 
proposed by Huestis et al (20) should be preferred over M d l 
I because it gives a better approximation f time of cannabis or 
dronabinol ingestion. The CIF yields a rough estimation of 
the fitness to drive. As far as oral intake is concerned, the sum 
of THC and 11-OH-THC provides a better estimate than THC 
alone of cannabis- or dronabinol-associated impairment. 
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